AptarGroup, Inc. ATR is poised to gain from its business transformation plan and improve organizational effectiveness. Innovative product launches and acquisitions will also fuel growth.

Let us delve deeper and analyze the factors that make this stock worth buying at present.

What’s Driving ATR’s Performance?

Focus on Business Transformation: AptarGroup has been focused on business transformation plans to drive top-line growth, boost operational excellence, enhance its approach to innovation and improve organizational effectiveness. 

The company has primarily been focused on transforming its Beauty segment, adding capabilities in Asia, implementing the latest commercial strategies, reducing costs and capitalizing on fast-growing application fields. The company’s cost-control measures and pricing actions will help sustain margins in the upcoming quarters.

Healthy Segmental Demand: The Pharma segment is witnessing healthy demand for its proprietary dispensing devices used for nasal decongestants, eye care, cough and cold, and saline rinses, as well as allergic rhinitis, emergency medicines and depression therapies. Demand for elastomeric components used for biologics continues to be strong. 

The company anticipates its unique pharma medication delivery systems to continue to increase in 2025, maintaining its long-term core sales target of 7-11%.

The Beauty segment is also seeing higher sales in prestige and mass fragrances, along with sales growth of skin care and color cosmetic solutions. A positive mix of pricing and volume growth will further aid the segment’s revenues.

Strategic Acquisitions: AptarGroup remains committed to expanding its business through acquisitions to expand the scope of technologies, geographic presence and product offerings. 

In February 2024, Aptar Digital Health acquired Healint, a digital health company, aligning with its strategy to expand its portfolio in neurology and strengthen its global footprint for digital health deployment. Aptar Digital Health also signed an enterprise agreement in February 2024 with Biogen, a leading global biotechnology company, to operate and develop their digital health solutions. 

In October 2024, AptarGroup acquired SipNose Nasal Delivery Systems' device technology assets. The acquisition expands Aptar Pharma's intellectual property and drives growth in intranasal delivery product development and research.

Innovative Product Launches: AptarGroup is poised to benefit from innovative product launches and remains the preferred choice for renowned brands worldwide. In 2023, the Pharma segment had the highest number of product launches since 2018. The momentum continued in 2024 and 2025.

In the first quarter of 2025, the Pharma segment’s nasal delivery System was the chosen solution for nasal saline rinse in Germany. The company’s ophthalmic squeeze dispenser is being used as a solution for multi-dose, preservative-free drops in China. A clinical validation study is underway for the SmartTrack services platform, developed over nearly a decade to reduce clinical trials for generic inhaled drugs using in-vitro-in-silico methods. The study, scheduled for the second quarter of 2025, aims to enhance the platform's effectiveness.

In the Beauty segment, ATR’s refillable fragrance pump is used for L'Oreal's Yves Saint Laurent fragrance in Europe, while O Boticario has selected its pump for a men's fragrance in Latin America. The company’s custom dispensing pump is used on Beiersdorf's Eucerin lotion, and a customized cosmetics pump is featured on P&G's OLAY serum in Asia. In the United States, its buildable drop-by-drop dispenser is used on the BYOMA suncare brand.

In Closures, Hidden Valley Ranch inverted salad dressing features ApartGroup's innovative lightweight closure with a fully recyclable valve, which is available in grocery stores in North America. In Latin America, L'Oreal's Garnier Fructis hair care products feature a fully recyclable e-commerce-capable disc top solution.

Story Continues

AptarGroup Stock’s Price Performance

ATR shares have gained 7.8% in the past year against the industry’s decline of 6.3%.Zacks Investment Research

Image Source: Zacks Investment Research

ATR Zacks Rank & Other Stocks to Consider

AptarGroup currently flaunts a Zacks Rank #1 (Strong Buy).

Some other top-ranked stocks from the Industrial Products sector are Life360, Inc. LIF, IHI Corporation IHICY and Federal Signal Corporation FSS. LIF and IHICY sport a Zacks Rank #1, and FSS has a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here.

Life360 delivered an average trailing four-quarter earnings surprise of 415%. The Zacks Consensus Estimate for LIF’s 2025 earnings is pinned at 24 cents per share, which indicates a year-over-year upsurge of 500%. Life360’s shares have skyrocketed 125% in a year.

The Zacks Consensus Estimate for IHI Corp’s 2025 earnings is pegged at $1.26 per share, indicating a year-over-year increase of 3.8%. IHICY’s shares have soared 272% in a year.

Federal Signal delivered an average trailing four-quarter earnings surprise of 6.4%. The Zacks Consensus Estimate for FSS’s 2025 earnings is pinned at $3.83 per share, which indicates year-over-year growth of 14.6%. The company’s shares have gained 10% in a year.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AptarGroup, Inc. (ATR):Free Stock Analysis Report

Federal Signal Corporation (FSS):Free Stock Analysis Report

IHI CORP (IHICY):Free Stock Analysis Report

Life360, Inc. (LIF):Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments